Home/Filings/4/0001209191-23-035579
4//SEC Filing

Mottiwala Aziz 4

Accession 0001209191-23-035579

CIK 0001819790other

Filed

Jun 7, 8:00 PM ET

Accepted

Jun 8, 7:16 PM ET

Size

11.2 KB

Accession

0001209191-23-035579

Insider Transaction Report

Form 4
Period: 2023-06-06
Mottiwala Aziz
Chief Commercial Officer
Transactions
  • Sale

    Common Stock

    2023-06-07$19.34/sh2,500$48,35048,186 total
  • Sale

    Common Stock

    2023-06-06$18.61/sh2,143$39,88150,686 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022.
  • [F2]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.07 to $18.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $19.02 to $19.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother

Related Parties

1
  • filerCIK 0001788542

Filing Metadata

Form type
4
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 7:16 PM ET
Size
11.2 KB